NAVIDEA BIOPHARMACEUTICALS I (NAVB) Stock Analyst Ratings

NYSEARCA:NAVB • US63937X2027

0.0779 USD
0 (-2.99%)
Last: Oct 5, 2023, 08:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Buy % Consensus

83

ChartMill assigns a Buy % Consensus number of 83% to NAVB. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 5.1. This target is 6446.85% above the current price.
  • NAVB was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about NAVB.
  • In the previous month the buy percentage consensus was at a similar level.
  • NAVB was analyzed by 7 analysts. More opinions would make the average more meaningful.

Related screens

Find peers with buy consensus above 85%
NAVB Historical Analyst RatingsNAVB Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Price Target & Forecast

Price Low Median Mean High 0.085.055.105.105.25 - 6,382.67% 6,446.85% 6,446.85% 6,639.41%

Related screens

Find peers 30% below price target
NAVB Current Analyst RatingNAVB Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0
Up and Down Grades

NAVIDEA BIOPHARMACEUTICALS I / NAVB FAQ

Can you provide the average price target for NAVIDEA BIOPHARMACEUTICALS I stock?

7 analysts have analysed NAVB and the average price target is 5.1 USD. This implies a price increase of 6446.85% is expected in the next year compared to the current price of 0.0779.


What is the consensus rating for NAVIDEA BIOPHARMACEUTICALS I (NAVB) stock?

The consensus rating for NAVIDEA BIOPHARMACEUTICALS I (NAVB) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.